Allegro completes enrollment in lung cancer Dx trial

Allegro Diagnostics has reached a major milestone in development of its new BronchoGen molecular diagnostic test for lung cancer: Enrollment is finally complete in the Maynard, MA-company's 1,320-patient AEGIS II clinical trial. Researchers are testing how well BronchoGen works along with a bronchoscopy to detect early signs of lung cancer, compared to a bronchoscopy alone. Data from the trial is expected by mid-2013. Allegro President and CEO Michael Webb told FierceMedicalDevices earlier this summer that the company is working to raise between $15 million and $20 million in Series B financing to help complete clinical testing and fuel an early 2013 commercial launch of the BronchoGen product. Release

Suggested Articles

J&J’s Ethicon unit received an FDA clearance for its Vistaseal applicators that spray a biologic sealant from Grifols to help stem surgical bleeding.

Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.